XBI, the SPDR S&P Biotech ETF, carries one of the most unusual positioning setups in the US market right now — short interest that dwarfs the available float, yet a borrow cost that has been falling steadily for weeks.
The headline short figure is striking. Short interest runs at roughly 117% of free float, a reading that, on a single stock, would typically signal extreme conviction or the early stages of a squeeze. For an ETF, the mechanics are different — authorised participants can create and redeem shares continuously, so short interest exceeding 100% of float is unusual but not inherently explosive. What matters more is the direction of travel. Shorts added roughly 5% over the past week, with the bulk of that jump arriving around August 11-12, when borrowed shares climbed from ~74 million to ~78 million, a level that has held steady since. The one-month change confirms the same story: shorts are modestly heavier than they were 30 days ago.
The lending market tells a quietly contrarian story. Despite a short position large enough to cover the entire float and then some, availability has actually eased — it now sits at roughly 101%, meaning the pool of shares available to borrow is broadly equal in size to short interest itself. That is a significant loosening from the tight conditions seen in early July, when availability dropped as low as 27% and borrowing 10 shares meant competing for fewer than 3 available. Cost to borrow has followed availability lower, falling 25% over the past week to 1.62% — the lowest level in six weeks and well off the 2.78% peak seen in early July. Easier borrow at a lower cost means the short position is cheaper to carry and the lending pool is not under stress.
Options positioning reinforces the cautious-but-not-extreme read. The put/call ratio is 1.12, slightly below its 20-day average of 1.16, with a z-score of -0.74 — mildly less defensive than usual, not a signal of panic. The ratio has drifted lower since late July, when it was running nearer 1.27. The 52-week range on the PCR stretches from 0.91 all the way to 2.44, so current levels sit in roughly the middle of the band. Options traders are hedging, as they typically do on a biotech basket, but there is no unusual accumulation of downside protection visible in the data.
The ORTEX short score rounds out the picture. It has been elevated all month, running between 74 and 80, and the latest reading of 78.5 puts XBI in the upper end of that band — high enough to reflect the abnormal short position, but not at a new extreme. The combined score of 78.3 has been broadly stable, suggesting the overall short setup has not materially tightened or loosened in aggregate terms, even as individual components like availability and borrow cost have shifted.
What to watch next: the divergence between a heavy and growing short position and a loosening borrow market is the central tension here — any catalyst that drives a surge in ETF creation activity, or a sharp biotech sector move that reshapes the underlying basket, would be the most natural test of whether that divergence resolves cleanly or disruptively.
See the live data behind this article on ORTEX.
Open XBI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
